An observational study in Gastrointestinal Cancer, sponsored by Qidong Gaitianli Medicines Co., Ltd. Status unknown at 12 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-10-25.
Sponsored by Qidong Gaitianli Medicines Co., Ltd · Observational
Registration of patients after gastrointestinal cancer radical surgery, including the information of treatments, recurrence \& metastasis, adverse events,etc.
This study adopts a multicenter, open, and registered research method, and plans to include 840 cases, including 360 cases in the Huaier Granule test group, 360 cases in the radiotherapy and chemotherapy control group, and 120 cases in the blank group. Using natural grouping, the registered objects are not pre grouped or queue divided, and the diagnosis, treatment, efficacy, and safety of gastrointestinal malignant tumor patients are accurately recorded under real conditions.
795 studies on the registry are indexed under Gastrointestinal Neoplasms; 235 are open to participants now.
This study's enrollment of 740 is above the median of 198 across 181 observational studies indexed under Gastrointestinal Neoplasms.
Browse Gastrointestinal Neoplasms studies →Qidong Gaitianli Medicines Co., Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients after gastrointestinal cancer radical surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Huaier Granule
Radiotherapy or chemotherapy
treatment abandoned
Huaier Granule \& Radiotherapy or chemotherapy
Disease free survival (DFS)
Time from enrollment to tumor recurrence or death with any cause
Time frame: Up to 2 years
Disease situation
Generally refers to tumor staging, classification, surgical methods, etc
Time frame: Baseline period
Quality of Life Score
Evaluate the quality of life of subjects during the trial by using the SF-36 scale.Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.
Time frame: Up to 2 years
Postoperative treatment methods
Generally including treatment plan, compliance, etc
Time frame: Up to 2 years
Concomitant medication
Other drugs (including chemical drugs, biological products, traditional Chinese patent medicines and simple preparations) taken by the subject in addition to the conventional research drugs during the clinical trial.
Time frame: Up to 2 years
Ran from Feb 2017 to primary completion in Oct 2023, 80 months.
Of 98 observational studies under Gastrointestinal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 16. This study's 80 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qidong Gaitianli Medicines Co., Ltd